Cereno Scientific Overview

  • Founded
  • 2012

Founded

  • Status
  • Public

  • Employees
  • 4

Employees

  • Stock Symbol
  • CRNO B

Stock Symbol

  • Share Price
  • $0.25
  • (As of Wednesday Closing)

Cereno Scientific General Information

Description

Cereno Scientific AB is developing a pipeline of preventive therapeutics to treat cardiovascular and rare diseases by epigenetic modulation through histone deacetylase inhibition (HDACi). The company's lead program, CS1, is a phase two dual-acting antithrombotic drug aimed at venous thrombosis and stroke prevention for atrial fibrillation. Cereno Scientificalso evaluates the potential of epigenetic modulation for rare diseases related to pulmonary fibrosis, thrombosis, inflammation, and high blood pressure in the pulmonary circulation system.

Contact Information

Website
www.cerenoscientific.se
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Stock Exchange
STO
Primary Office
  • BioVentureHub
  • Pepparedsleden 1
  • 431 83 Molndal
  • Sweden
+46 076-866 00 00

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Cereno Scientific Stock Performance

(As of Wednesday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$0.25 $0.25 $0.04 - $0.31 $59.8M 234M 4.01M -$0.02

Cereno Scientific Financials Summary

In Thousands,
USD 		TTM 30-Jun-2023 FY 2022 31-Dec-2022 FY 2021 31-Dec-2021 FY 2020 31-Dec-2020
EV 10,746 18,272 38,191 9,144
Revenue 0 0 0 0
EBITDA (2,936) (2,709) (1,746) (1,706)
Net Income (2,927) (2,726) (1,893) (1,737)
Total Assets 23,895 20,673 19,971 13,682
Total Debt 37 38 575 1,161
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Cereno Scientific Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA		 Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Cereno Scientific‘s full profile, request access.

Request a free trial

Cereno Scientific Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Cereno Scientific AB is developing a pipeline of preventive therapeutics to treat cardiovascular and rare diseases by ep
Drug Discovery
Molndal, Sweden
4 As of 2022
000.00
000000000 000.00

000000

laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in repreh
0000 000000000
Solna, Sweden
00 As of 0000
000.00
00000000000 000.00

000000

t aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in vol
0000 000000000
Holte, Denmark
00 As of 0000
00.000
00000 00000 00.000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Cereno Scientific Competitors (2)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
AnaCardio Venture Capital-Backed Solna, Sweden 00 000.00 00000000000 000.00
00000000 000000 Venture Capital-Backed Holte, Denmark 00 00.000 00000 00000 00.000
You’re viewing 2 of 2 competitors. Get the full list »

Cereno Scientific Patents

  • 45

    Total Documents Applications and Grants

  • 000

    Total Patents Families

  • 3

    Granted

  • 1

    Pending

  • 000

    Expiring in next 12 mo

Cereno Scientific Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
GB-2613900-A Novel compounds and methods of use thereof Pending 20-Dec-2021 0000000000 0
GB-202002006-D0 Compositions comprising histone deacetylase inhibiting compounds, and uses thereof Inactive 13-Feb-2020
GB-202001869-D0 New compounds Inactive 11-Feb-2020
GB-202001868-D0 Compositions comprising histone deacetylase inhibiting compounds, and uses thereof Inactive 11-Feb-2020
GB-202001867-D0 Compositions comprising histone deacetylase inhibiting compounds, and uses thereof Inactive 11-Feb-2020
To view Cereno Scientific’s complete patent history, request access »

Cereno Scientific Executive Team (7)

Name Title Board Seat Contact Info
Sten Sörensen Chief Executive Officer
Daniel Brodén Chief Financial Officer
Etienne Adriansen Chief Business Officer
Niklas Bergh Senior Advisor & Co-Founder
Sverker Jern Co-Founder & Board Member
You’re viewing 5 of 7 executive team members. Get the full list »

Cereno Scientific Board Members (2)

Name Representing Role Since
Jonas Säljö Ph.D Cereno Scientific Board Member 000 0000
Sverker Jern Cereno Scientific Co-Founder & Board Member 000 0000
To view Cereno Scientific’s complete board members history, request access »

Cereno Scientific Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial